# Silverarc Capital Management, LLC 13F Q2 2026: $962 million

Silverarc Capital Management, LLC reported $962 million in 13F securities across 73 positions for the quarter ended June 30, 2026, in a holdings report filed August 13, 2026. Its largest holding was Ascendis Pharma A/S at $55 million, 5.7% of the reported value. Since Q1 2026 it opened 26 new positions and exited 26.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $962,154,050
- Positions: 73
- Filed: August 13, 2026
- Report type: 13F holdings report
- CIK: 1816307
- Form 13F file number: 028-21010
- Business address: 20 Park Plaza Suite 620, Boston, MA 02116
- SEC filing: [0001420506-26-001563](https://www.sec.gov/Archives/edgar/data/1816307/000142050626001563/0001420506-26-001563-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/silverarc-capital-management-llc-304220)

## Top 25 holdings by value

The largest of 73 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 206,234 | $55 million | New |
| [Celcuity Inc](https://specstream.ai/data/institutional-holders/celcuity-inc-15102k100) | COM | 500,996 | $52.4 million | +143,093 |
| [Cogent Biosciences Inc](https://specstream.ai/data/institutional-holders/cogent-biosciences-inc-19240q201) | COM | 1,280,707 | $49.6 million | -33,482 |
| [Urogen Pharma LTD](https://specstream.ai/data/institutional-holders/urogen-pharma-ltd-m96088105) | COM | 1,301,979 | $47.9 million | -201,066 |
| [Immunome Inc](https://specstream.ai/data/institutional-holders/immunome-inc-45257u108) | COM | 2,017,009 | $42.7 million | +166,731 |
| [Dianthus Therapeutics Inc](https://specstream.ai/data/institutional-holders/dianthus-therapeutics-inc-252828108) | COM | 390,000 | $38 million | -264,746 |
| [Rhythm Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/rhythm-pharmaceuticals-inc-76243j105) | COM | 311,461 | $34.6 million | +5,461 |
| [Oruka Therapeutics Inc](https://specstream.ai/data/institutional-holders/oruka-therapeutics-inc-687604108) | COM | 352,802 | $33.6 million | +201,894 |
| [Monte Rosa Therapeutics Inc](https://specstream.ai/data/institutional-holders/monte-rosa-therapeutics-inc-61225m102) | COM | 1,108,295 | $26.8 million | -893,745 |
| [Syndax Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/syndax-pharmaceuticals-inc-87164f105) | COM | 1,214,390 | $26.5 million | +325,403 |
| [Enliven Therapeutics Inc](https://specstream.ai/data/institutional-holders/enliven-therapeutics-inc-29337e102) | COM | 489,382 | $24.8 million | New |
| [Immunovant Inc](https://specstream.ai/data/institutional-holders/immunovant-inc-45258j102) | COM | 619,096 | $23.9 million | +204,860 |
| [Erasca Inc](https://specstream.ai/data/institutional-holders/erasca-inc-29479a108) | COM | 1,263,026 | $23.1 million | -588,786 |
| [Sagimet Biosciences Inc](https://specstream.ai/data/institutional-holders/sagimet-biosciences-inc-786700104) | COM SER A | 2,927,698 | $22.6 million | New |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 169,593 | $22.6 million | -132,937 |
| [Praxis Precision Medicines I](https://specstream.ai/data/institutional-holders/praxis-precision-medicines-i-74006w207) | COM NEW | 65,679 | $22 million | -5,873 |
| [Kodiak Sciences Inc](https://specstream.ai/data/institutional-holders/kodiak-sciences-inc-50015m109) | COM | 546,256 | $21.3 million | -445,674 |
| ARK ETF TR | GENOMIC REV ETF (put) | 500,000 | $21 million | New |
| [Definium Therapeutics Inc](https://specstream.ai/data/institutional-holders/definium-therapeutics-inc-24477v105) | COM SHS | 400,000 | $18.8 million | New |
| [Veracyte Inc](https://specstream.ai/data/institutional-holders/veracyte-inc-92337f107) | COM | 318,001 | $18.7 million | +138,301 |
| Syndax Pharmaceuticals Inc | CALL (call) | 693,600 | $15.2 million | +373,600 |
| [Guardant Health Inc](https://specstream.ai/data/institutional-holders/guardant-health-inc-40131m109) | COM | 99,826 | $15 million | +1,312 |
| [C4 Therapeutics Inc](https://specstream.ai/data/institutional-holders/c4-therapeutics-inc-12529r107) | COM STK | 3,032,060 | $14.2 million | +1,120,275 |
| [Zenas Biopharma Inc](https://specstream.ai/data/institutional-holders/zenas-biopharma-inc-98937l105) | COM | 509,789 | $12.9 million | -626,146 |
| [Trevi Therapeutics Inc](https://specstream.ai/data/institutional-holders/trevi-therapeutics-inc-89532m101) | COM | 678,095 | $12.6 million | +166,968 |

## New positions in Q2 2026

26 positions not in the filing for the quarter ended March 31, 2026. The 25 largest are shown.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 206,234 | $55 million |
| [Enliven Therapeutics Inc](https://specstream.ai/data/institutional-holders/enliven-therapeutics-inc-29337e102) | COM | 489,382 | $24.8 million |
| [Sagimet Biosciences Inc](https://specstream.ai/data/institutional-holders/sagimet-biosciences-inc-786700104) | COM SER A | 2,927,698 | $22.6 million |
| ARK ETF TR | GENOMIC REV ETF (put) | 500,000 | $21 million |
| [Definium Therapeutics Inc](https://specstream.ai/data/institutional-holders/definium-therapeutics-inc-24477v105) | COM SHS | 400,000 | $18.8 million |
| [Alx Oncology Hldgs Inc](https://specstream.ai/data/institutional-holders/alx-oncology-hldgs-inc-00166b105) | COM | 5,744,757 | $11.9 million |
| [Veradermics Inc](https://specstream.ai/data/institutional-holders/veradermics-inc-922967104) | COMMON STOCK | 95,000 | $11.7 million |
| [Avalyn Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/avalyn-pharmaceuticals-inc-05348y105) | COM SHS | 330,487 | $10.9 million |
| [Aclaris Therapeutics Inc](https://specstream.ai/data/institutional-holders/aclaris-therapeutics-inc-00461u105) | COM | 1,946,482 | $10.3 million |
| [Avalo Therapeutics Inc](https://specstream.ai/data/institutional-holders/avalo-therapeutics-inc-05338f306) | COM NEW | 500,402 | $9.2 million |
| [Genedx Holdings Corp](https://specstream.ai/data/institutional-holders/genedx-holdings-corp-81663l200) | COM CL A | 122,269 | $8.4 million |
| Oric Pharmaceuticals Inc | CALL (call) | 682,600 | $7.4 million |
| Monte Rosa Therapeutics Inc | CALL (call) | 300,000 | $7.3 million |
| [Solid Biosciences Inc](https://specstream.ai/data/institutional-holders/solid-biosciences-inc-83422e204) | COM NEW | 668,450 | $6.7 million |
| Abivax SA | CALL (call) | 50,000 | $6.7 million |
| [Artiva Biotherapeutics Inc](https://specstream.ai/data/institutional-holders/artiva-biotherapeutics-inc-04317a107) | COM | 525,000 | $5.1 million |
| [Uniqure NV](https://specstream.ai/data/institutional-holders/uniqure-nv-n90064101) | SHS | 105,000 | $4.8 million |
| [Research Alliance Corp III](https://specstream.ai/data/institutional-holders/research-alliance-corp-iii-g75226103) | ORD SHS CL A | 360,000 | $3.9 million |
| [Karyopharm Therapeutics Inc](https://specstream.ai/data/institutional-holders/karyopharm-therapeutics-inc-48576u205) | COM NEW | 297,460 | $2.9 million |
| Kymera Therapeutics Inc | PUT (put) | 25,000 | $2.9 million |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155x100) | COM | 10,000 | $1.9 million |
| Absci Corporation | PUT (put) | 157,600 | $1.8 million |
| [Achieve Life Science Inc](https://specstream.ai/data/institutional-holders/achieve-life-science-inc-004468500) | COM | 227,178 | $1.5 million |
| [Connect Biopharma Hldgs LTD](https://specstream.ai/data/institutional-holders/connect-biopharma-hldgs-ltd-g23549101) | SHS | 545,000 | $1.3 million |
| [Cellectar Biosciences Inc](https://specstream.ai/data/institutional-holders/cellectar-biosciences-inc-15117f880) | COM NEW | 321,728 | $894,404 |

## Positions exited in Q2 2026

26 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then. The 25 largest are shown.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| SPDR Series Trust | PUT (put) | 825,000 | $105.4 million |
| Kalvista Pharmaceuticals Inc | COM | 2,876,407 | $57.9 million |
| [Nuvalent Inc](https://specstream.ai/data/institutional-holders/nuvalent-inc-670703107) | COM | 354,914 | $36.4 million |
| Ascendis Pharma A/S | SPONSORED ADR | 124,658 | $28.5 million |
| Centessa Pharmaceuticals PLC | SPONSORED ADS | 466,345 | $18.5 million |
| [Scholar Rock HLDG Corp](https://specstream.ai/data/institutional-holders/scholar-rock-hldg-corp-80706p103) | COM | 339,613 | $16.7 million |
| [CG Oncology Inc](https://specstream.ai/data/institutional-holders/cg-oncology-inc-156944100) | COM | 166,349 | $11.3 million |
| Uniqure NV | CALL (call) | 500,000 | $8.2 million |
| Celcuity Inc | CALL (call) | 54,500 | $6.2 million |
| [Celldex Therapeutics Inc New](https://specstream.ai/data/institutional-holders/celldex-therapeutics-inc-new-15117b202) | COM NEW | 178,378 | $5.7 million |
| [Cytokinetics Inc](https://specstream.ai/data/institutional-holders/cytokinetics-inc-23282w605) | COM NEW | 71,203 | $4.7 million |
| [Climb Bio Inc](https://specstream.ai/data/institutional-holders/climb-bio-inc-28658r106) | COM | 684,908 | $4.7 million |
| [Compass Therapeutics Inc](https://specstream.ai/data/institutional-holders/compass-therapeutics-inc-20454b104) | COM | 859,049 | $4.5 million |
| [Surrozen Inc](https://specstream.ai/data/institutional-holders/surrozen-inc-86889p208) | COM NEW | 144,255 | $4.2 million |
| [Zura Bio LTD](https://specstream.ai/data/institutional-holders/zura-bio-ltd-g9ty5a101) | CLASS A ORD SHS | 560,651 | $3.3 million |
| [Fulcrum Therapeutics Inc](https://specstream.ai/data/institutional-holders/fulcrum-therapeutics-inc-359616109) | COM | 419,949 | $3.2 million |
| [Annexon Inc](https://specstream.ai/data/institutional-holders/annexon-inc-03589w102) | COM | 496,461 | $2.8 million |
| [Monopar Therapeutics Inc](https://specstream.ai/data/institutional-holders/monopar-therapeutics-inc-61023l207) | COM NEW | 43,488 | $2.4 million |
| [Nextcure Inc](https://specstream.ai/data/institutional-holders/nextcure-inc-65343e207) | COM NEW | 176,057 | $1.9 million |
| [Neumora Therapeutics Inc.](https://specstream.ai/data/institutional-holders/neumora-therapeutics-inc-640979100) | COM | 818,156 | $1.6 million |
| [Edgewise Therapeutics Inc](https://specstream.ai/data/institutional-holders/edgewise-therapeutics-inc-28036f105) | COM | 42,615 | $1.3 million |
| [Replimune Group Inc](https://specstream.ai/data/institutional-holders/replimune-group-inc-76029n106) | COM | 171,936 | $1.3 million |
| [Generate Biomedicines Inc](https://specstream.ai/data/institutional-holders/generate-biomedicines-inc-370920100) | COM SHS | 100,000 | $1.3 million |
| Compass Therapeutics Inc | CALL (call) | 172,400 | $911,996 |
| Radiopharm Theranostics LTD | SPONSORED ADS | 187,406 | $805,846 |

## Also on SpecStream

- [Silverarc Capital Management, LLC Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1816307/000142050626001563/0001420506-26-001563-index.htm)
- [Silverarc Capital Management, LLC investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/silverarc-capital-management-llc-304220)
- [Largest 13F filers in Massachusetts](https://specstream.ai/data/institutional-holdings/state/massachusetts)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Boston, Massachusetts

- [Home builders in Boston, Massachusetts](https://specstream.ai/data/businesses/home-builders/boston-massachusetts-united-states)
- [Italian restaurants in Boston, Massachusetts](https://specstream.ai/data/businesses/italian-restaurants/boston-massachusetts-united-states)
- [Music schools in Boston, Massachusetts](https://specstream.ai/data/businesses/music-schools/boston-massachusetts-united-states)
- [Private schools in Boston, Massachusetts](https://specstream.ai/data/businesses/private-schools/boston-massachusetts-united-states)
- [Security companies in Boston, Massachusetts](https://specstream.ai/data/businesses/security-companies/boston-massachusetts-united-states)
- [Acupuncture clinics in Boston, Massachusetts](https://specstream.ai/data/businesses/acupuncture-clinics/boston-massachusetts-united-states)
